Study identifies genetic factors crucial in acute myeloid leukemia survival for Black patients

Researchers have led a global study that identified molecular predictors of survival among Black patients with acute myeloid leukemia (AML). The study suggests a need to modify current AML risk layers by including ancestry-specific genetic factors and testing those in clinical trials.

Powered by WPeMatico

Framework reveals how neglecting income, education and ethnicity affects disease spread predictions on COVID-19 data

An international team of researchers have developed an innovative approach to epidemic modeling that could transform how scientists and policymakers predict the spread of infectious diseases. Led by Dr. Nicola Perra, Reader in Applied Mathematics, the study published in Science Advances introduces a new framework that incorporates socioeconomic status (SES) factors—such as income, education, and ethnicity—into epidemic models.

Powered by WPeMatico

How much do so-called ‘health foods’ really contribute to nutrient intake?

A research group led by Professor Keiko Asakura and Assistant Professor Minami Sugimoto of the Faculty of Medicine at Toho University analyzed dietary intake data of the Japanese population collected in 2012. They assessed the contribution of so-called “health foods” (fortified foods and dietary supplements) to nutrient intake. This study is expected to be useful for the formulation of health policies aimed at improving nutrient intake in Japan.

Powered by WPeMatico

Zydus receives USFDA nod for Paliperidone ER Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg

Ahmedabad: Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9
mg (USRLD: Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg).

Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of
schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment
of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants.
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at
SEZ, Ahmedabad.

Read Also: Zydus Lifesciences bags tentative USFDA nod for Enzalutamide Tablets for prostate cancer

Paliperidone extended-release tablets had annual sales of USD XXX 47.1 in the United States
(IQVIA MAT July 2024).

The group now has 400 approvals and has so far filed over 465* ANDAs since the
commencement of the filing process in FY 2003-04.

Read Also: USFDA issues EIR for Zydus Lifesciences Pharmez transdermal patch manufacturing facility

Powered by WPeMatico

AIIMS specifies feeder qualifications for 72 DM, MCh courses

New Delhi: For super-specialisation in 72 DM and MCh courses across Institutes of National Importance (INI), the All India Institute of Medical Sciences (AIIMS) has notified the feeder qualifications for the INI SS January 2025 session.

Laying down the eligibility criteria in its prospectus for the Institute of National Importance Super-Speciality Entrance Test (INI SS) January 2025 session, the AIIMS detailed the prior/required or feeder qualifications for DM, MCh and MD Hospital administration courses. 

Institute of National Importance Super-Specialty Entrance Test (INI-SS)- The entrance test for admission into DM/M.Ch./MD Hospital Administration Courses at Institutes of National Importance (INI) for Medical Education namely, AIIMS-New Delhi and all new AIIMS, JIPMER-Puducherry, PGIMER-Chandigarh, NIMHANS-Bengaluru and Sree Chitra Tirunal Institute for Medical Sciences & Technology- Trivandrum is held twice in a year for January and July session of respective year. 

Feeder Qualifications:

All candidates who are vying for admission in DM and MCh courses at INIs are advised to take note of the following details: 

DM Courses Eligibility and Educational Qualification

S.No Institute Name Required Qualification
1. DM- ACUTE CARE-EMERGENCY MEDICINE(MS0701701)
(I) PGIMER MD Internal Medicine/General Medicine/ Emergency Medicine or Equivalent
2. DM-ADDICTION PSYCHIATRY(MS0705601)
(I) AIIMS M.D./DNB in Psychiatry of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) NIMHANS
3.DM-CARDIAC SURGICAL INTENSIVE CARE(MS0701002)HIATRY(MS0705601)
(I) AIIMS MD/DNB in Anaesthesia/Pediatrics/Medicine of this Institute or any other University or equivalent degree recognized by the NMC
4. DM-CARDIAC-ANAESTHESIA AND CRITICAL CARE/DM-CARDIOTHORACIC & VASCULAR ANESTHESIA*/Cardiac Anaesthesia & Intensive Care**/CTVS Anaesthesiology (MS0700801)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER**
(III) SCTIMST*
(Iv) JIPMER
5.DM-CARDIOLOGY(MS0700901)
(I) AIIMS M.D/DNB in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) SCTIMST M.D/DNB in General Medicine/Pediatrics of any Indian University or equivalent degree recognized by the NMC
(III) PGIMER MD in Medicine or equivalent
(Iv) JIPMER M.D/ DNB Degree in General Medicine / Pediatrics/ Pulmonary Medicine recognized by the NMC.
6.DM-CARDIOVASCULAR RADIOLOGY & ENDOVASCULAR INTERVENTIONS/DM-CARDIOVASCULAR IMAGING AND VASCULAR INTERVENTIONAL RADIOLOGY*(MS0701101)
(I) AIIMS M.D /DNB in Radio-Diagnosis or equivalent degree
(II) SCTIMST
(III) PGIMER M.D /DNB in Radio-Diagnosis/Radiology of any Indian University or equivalent degree recognized by the NMC
7.DM-CHILD AND ADOLESCENT PSYCHIATRY(MS0705602)
(I) PGIMER MD/DNB Psychiatry or equivalent
(II) NIMHANS
8.DM- CLINICAL HEMATOLOGY(MS0702501)
(I) AIIMS M.D/ DNB in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine or equivalent
9.DM-CLINICAL IMMUNOLOGY & RHEUMATOLOGY(MS0707201)
(I) AIIMS MD Medicine, MD Pediatrics
(II) PGIMER MD Medicine or equivalent
(III) JIPMER MD/DNB General Medicine/Pediatrics
10. DM-CLINICAL PHARMACOLOGY(MS0705201)
(I) AIIMS M.D/DNB in Medicine/Pharmacology/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Pharmacology or equivale
(III) JIPMER
11. DM-CRITICAL CARE MEDICINE/CRITICAL CARE*/DM-INTENSIVE CARE**(MS0700101)
(I) AIIMS M.D. in Anaesthesiology/Medicine/Chest Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER* M.D. in Anaesthesiology/ General Medicine/Pulmonary Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER** MD Anaesthesia/Internal Medicine or equivalent
12. DM-ENDOCRINOLOGY(MS0701901)
(I) AIIMS M.D./ DNB Degree in Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER M.D./ DNB Degree in General Medicine/Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER MD Medicine or equivalent
13. DM- FORENSIC PATHOLOGY/ (MS0702102)
(I) AIIMS MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC
14. DM-FORENSIC PSYCHIATRY(MS0705603)
(I) NIMHANS MD/DNB in Psychiatry
15. DM-FORENSIC RADIOLOGY & VIRTUAL AUTOPSY(MS0702103)
(I) AIIMS MD/DNB Forensic Medicine/Forensic Medicine and Toxicology recognized by Medical Council of India/NMC
16. DM-GASTROENTEROLOGY/MEDICAL GASTROENTEROLOGY* (MS0702201)
(I) AIIMS M.D/ DNB in Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine or equivalent
(III) JIPMER* M.D/ DNB in General Medicine /Pediatrics of this Institute or any other University or equivalent degree recognized by the NMC
17. DM-HEMATOPATHOLOGY(MS0702502)
(I) AIIMS M.D/DNB in Pathology/Lab. Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Pathology or equivalent
18. DM-HEPATOLOGY(MS0702202)
PGIMER MD Medicine/Pediatrics or equivalent
19. DM- HIGH ALTITUDE MEDICINE (MS0705401)
(I) AIIMS MD/DNB Internal Medicine/Physiology/Anaesthesia/Community Medicine recognized by Medical Council of India
20. DM-HISTOPATHOLOGY(MS0705102)
(I) PGIMER MD Pathology or equivalent
21. DM-HOSPITAL MEDICINE & CRITICAL CARE (MS0708001)
(I) AIIMS MD in Internal Medicine, Geriatric Medicine
22. DM-INFECTIOUS DISEASES/ CLINICAL INFECTIOUS DISEASES ( MS0702701)
(I) AIIMS M.D/DNB in Medicine/Pediatrics/Microbiology/Tropical Medicine of this Institute or any other University or equivalent degree recognized bythe NMC
(II) AIIMS (Raipur) M.D/DNB in General Medicine/Pediatrics /Tropical Medicine or an equivalent qualification as recognized by Medical Council of India/NMC
(III) PGIMER MD/DNB is internal/General medicine
23. DM-INTERVENTIONAL RADIOLOGY(MS0705801)
(I) AIIMS MD/DNB (Radiology/Radio diagnosis) recognized by MCI/NMC
(II) PGIMER MD/DNB in Radio-diagnosis or equivalent
24. DM-MEDICAL AND FORENSIC TOXICOLOGY (MS0702101)
(I) AIIMS MD/DNB In forensic Medicine or forensic Medicine &Toxicology/Pharmacology/Emergency Medicine/Internal/General Medicine/Paediatrics recognized by Medical Council of India/ NMC
25. DM-MEDICAL GENETICS(MS0704901)
(I) AIIMS MD in Paediatrics/Medicine/Obstetrics and Gynaecology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Paediatrics or equivalent
26. DM-MEDICAL ONCOLOGY(MS0702901)
(I) AIIMS M.D/DNB in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) JIPMER M.D. / DNB Degree in Medicine / Pediatrics /Radiotherapy recognized by the Medical Council of India.
27. DM-NEONATOLOGY(MS0704902)
(I) AIIMS M.D Degree in Paediatrics of this Institute or any other University or (II) PGIMER equivalent degree recognized by the NMC
(II) JIPMER M.D/DNB in General Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(III) PGIMER MD in Medicine or equivalent
29. DM-NEURO-ANAESTHESIOLOGY & CRITICAL CARE/DM-NEURO ANAESTHESIA*/NEUROANAESTHESIA AND NEUROCRITICAL CARE**(MS0703301)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER*
(III) SCTIMST*
(Iv) NIMHANS**
(v) JIPMER
30. DM-NEUROIMAGING AND INTERVENTIONAL NEURORADIOLOGY/NEUROIMAGING AND INTERVENTIONS(MS0703501)
(I) AIIMS M.D./ DNB Degree in Radio diagnosis of this Institute or any other University or equivalent degree recognized by the NMC
(II) NIMHANS
(III) JIPMER
(Iv) PGIMER M.D./DNB in Radiology or equivalent
(v) SCTIMST M.D./ DNB Degree in Radio diagnosis/Radiology of any Indian university or equivalent degree recognized by the NMC
31. DM-NEUROLOGY(MS0703401)
(I) AIIMS M.D. in Medicine/Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) JIPMER M.D. in General Medicine/Paediatrics of any Indian University or equivalent degree recognized by the NMC
(III) SCTIMST
(Iv) NIMHANS M.D./DNB in Internal (General) Medicine/Paediatrics
(v) PGIMER MD in Medicine or equivalent
32. DM-NEUROPATHOLOGY(MS0707301)
(I) NIMHANS MD/DNB in Pathology
33. DM-ONCO-ANAESTHESIA(MS0704301)
(I) AIIMS M.D/ DNB in Anaesthesiology of this Institute or any other University or equivalent degree recognized by the NMC
34. DM-PAEDIATRIC ANAESTHESIA & INTENSIVE CARE(MS0700103)
PGIMER MD Anaesthesia or equivalent
35. DM-PAEDIATRIC CARDIOLOGY(MS0700902)
(I) AIIMS M.D.in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
(III) SCTIMST
36. DM-PAEDIATRIC CLINICAL IMMUNOLOGY AND RHEUMATOLOGY(MS0704908)
(I) PGIMER MD Paediatrics or equivalent
37. DM- PAEDIATRIC EMERGENCY MEDICINE (MS0704912)
(I) AIIMS MD/DNB Paediatrics or Emergency Medicine recognized by Medical Council of India/NMC
38. DM-PAEDIATRIC ENDOCRINOLOGY(MS0704907)
(I) AIIMS MD Paediatrics or equivalent
(II) PGIMER
39. DM-PAEDIATRIC GASTROENTEROLOGY & HEPATOLOGY/PAEDIATRIC GASTROENTEROLOGY*(MS0707101)
(I) AIIMS MD/DNB Paediatrics or equivalent
(II) PGIMER
40. DM-PAEDIATRIC HAEMATOLOGY-ONCOLOGY(MS0704909)
(I) AIIMS MD/DNB Paediatrics or equivalent
(II) PGIMER
41. DM-PAEDIATRIC NEPHROLOGY(MS0704903)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
42. DM-PAEDIATRIC NEUROLOGY(MS0704904)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER
43. DM-PAEDIATRIC PULMONOLOGY & INTENSIVE CARE(MS0704905)
(I) AIIMS M.D/DNB in Paediatrics of this Institute or any other University or equivalent degree recognized by the NMC
44. DM-PAEDIATRIC PULMONOLOGY(MS0704910)
(I) AIIMS MD Paediatrics or equivalent
(II) PGIMER
45. DM-PAEDIATRICS CRITICAL CARE(MS0704911)
(I) AIIMS MD/DNB Degree in Paediatrics or equivalent
(II) PGIMER
(III) JIPMER
46. DM- PAIN MEDICINE (MS0700104)
(I) AIIMS MD(Anaesthesiology) or equivalent
47. DM-PULMONARY CRITICAL CARE & SLEEP MEDICINE(MS0705701)
(I) AIIMS M.D in Medicine/MD Pulmonary Medicine/MD Chest Medicine/MD Respiratory Medicine of this Institute or any other University or equivalent degree recognized by the NMC
(II) PGIMER MD Medicine/Respiratory Diseases or equivalent
48. DM-THERAPEUTIC NUCLEAR MEDICINE(MS0703802)
(I) AIIMS M.D in Nuclear Medicine of this Institute or any other University orequivalent degree recognized by the NMC
49. DM-PAEDIATRIC ANAESTHESIOLOGY (MS0704913)
(I) AIIMS MD Anaesthesiology
50. DM-VIROLOGY (MS0708201)
(I) AIIMS MD Microbiology
51. DM-GLOBAL HEALTH & CLINICAL EPIDEMIOLOGY (MS0708301)
(I) AIIMS MD in Community Medicine, Family Medicine, Paediatrics, General (Internal) Medicine, and Geriatrics Medicine of this Institute or any other University or equivalent degree recognized by the NMC
52. DM-METABOLISM MEDICINE/METABOLIC MEDICINE (MS0700301)
(I) AIIMS MD Biochemistry/MD Medicine/MD Paediatrics/MD Internal Medicine/MD CFM from an Institute recognised by MCI
53. DM-PSYCHOSOMATIC MEDICINE (MS0708401)
(I) AIIMS M.D/DNB in Psychiatry of this Institute of any other University or equivalent degree recognized by the NMC.

M.Ch Courses Eligibility and Educational Qualification

54.M.Ch-BREAST, ENDOCRINE AND GENERAL SURGERY(MS0806301)
(I) AIIMS M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER MS (Surgery/General Surgery/equivalent)
55.M.Ch.- C.T.V.S/CVTS*(MS0801001)
(I) AIIMS M.S./DNB degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER*
(IV) SCTIMST*
56. M.CH-CORNEA, CATARACT AND REFRACTIVE SURGERY(MS0804501)
(I) AIIMS MD/MS Ophthalmology or equivalent
57. M.Ch-G.I. SURGERY/SURGICAL GASTROENTEROLOGY(MS0802301)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER
58. M.Ch-GYNAECOLOGIC ONCOLOGY(MS0804402)
(I) AIIMS MD/MS in Obstetrics & Gynaecology of this Institute or any other University or equivalent degree recognized by MCI
(II) JIPMER
59. M.CH. HAND AND MICROVASCULAR SURGERY (MS0805502)
(I) AIIMS M.S degree in General Surgery/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the NMC/MCI
60. M.Ch-HEAD-NECK SURGERY AND ONCOLOGY / HEAD & NECK SURGERY*(MS0804801)
(I) AIIMS M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER*
61. M.CH. JOINT REPLACEMENT & RECONSTRUCTION(MS0804702)
(I) AIIMS MS/DNB Orthopaedics or an equivalent degree recognized by Medical Council of India/NMC.
62. M.Ch-MINIMAL ACCESS SURGERY & GENERAL SURGERY(MS0806302)
(I) AIIMS M.S. degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
63. M.Ch-NEURO-SURGERY(MS0803601)
(I) AIIMS M.S./DNB degree in Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER
(III) NIMHANS M.S./DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(Iv) JIPMER
(v) SCTIMST
64. M.CH.-PAEDIATRIC ORTHOPEDICS SURGERY/ PAEDIATRIC ORTHOPEDICS(MS0804701)
(I) AIIMS* MS/DNB Orthopaedics or equivalent
(II) PGIMER
65. M. Ch.-PAEDIATRIC SURGERY(MS0805001)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER
(III) PGIMER
66. M.Ch-PLASTIC AND RECONSTRUCTIVE SURGERY/PLASTIC SURGERY*(MS0805501)
(I) AIIMS M.S degree in Surgery/ENT/Orthopaedics of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER*
(III) JIPMER M.S /DNB degree in General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
67. M.CH. -RENAL TRANSPLANT SURGERY(MS0803202)
(I) PGIMER MS Surgery or equivalent
68.M.Ch-SURGICAL ONCOLOGY(MS0806401)
(I) AIIMS M.S degree in Surgery/ENT of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) JIPMER M.S./ DNB Degree in General Surgery / Obstetrics & Gynaecology / Otorhinolaryngology (E.N.T) / Orthopaedics Surgery recognized by the MCI.
69. M.Ch-TRAUMA SURGERY AND CRITICAL CARE(MS0806701)
(I) AIIMS M.S degree in Surgery/Trauma and Emergency Surgery of this Instituteor any other University or any other equivalent degree recognized by the MCI
70.M.Ch-UROLOGY(MS0806801)
(I) AIIMS M.S. degree in Surgery/General Surgery of this Institute or any other University or any other equivalent degree recognized by the MCI
(II) PGIMER
(III) JIPMER
71. M.CH- VASCULAR SURGERY (MS0808101)
(I) SCTIMST MS/DNB in Gen. Surgery/Equivalent degree recognized by NMC
72. M.Ch- SPORTS INJURY (MS0806702)
(I) AIIMS M.S Orthopaedics /DNB Orthopaedics from any recognized institution

Powered by WPeMatico

UNFPA Commends India’s monumental efforts in reducing MMR by 70% between 2000 and 2020

New Delhi: The United Nations Population Fund (UNFPA) has recognized India’s extraordinary progress in advancing Maternal Health and Family Planning. 

Dr Natalia Kanem, Executive Director of UNFPA, felicitated Smt. Punya Salila Srivastava, Union Health Secretary, by presenting a plaque and certificate and underlined UNFPA’s unwavering commitment to partnering with India toward women’s health and well-being.

The Ministry of Health and Family Welfare is implementing a number of programmes to improve maternal health outcomes toward achieving zero preventable maternal deaths. These include assured quality and respectful maternity care under the Surakshit Matritva Aashwasan Yojana (SUMAN), Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) and the Midwifery Services Initiative.

Also Read:India’s Maternal Mortality Ratio improves by 6 points, achieves National Health Policy target

In the presence of Smt. Aradhana Patnaik, Additional Secretary and Mission Director, National Health Mission; Smt. Meera Srivastava, Joint Secretary, Reproductive & Child Health (RCH); Mr. Pio Smith, Asia Pacific Regional Director for UNFPA; and Ms. Andrea M. Wojnar, UNFPA India Representative, Dr. Kanem commended India’s monumental efforts in reducing the Maternal Mortality Ratio (MMR) by an impressive 70% between 2000 and 2020, positioning the country to achieve the Sustainable Development Goal (SDG) target of an MMR below 70 before 2030. This remarkable progress has saved the lives of thousands of women across the country, particularly those from marginalized communities.

India’s Family Planning program has reached new heights, with the Total Fertility Rate reduced below the replacement level (TFR-2). Over the years, UNFPA has played a key role in expanding the basket of contraceptive choices, including the recent inclusion of Subdermal Implants and injectable Depot Medroxyprogesterone Acetate (DMPA).

The Ministry’s leadership in global reproductive health forums was acknowledged with India holding key positions in the Partnership for Maternal, Newborn & Child Health (PMNCH) and the Family Planning 2030 (FP2030) global partnership.

During the meeting, Dr. Kanem reaffirmed UNFPA’s steadfast commitment to supporting India’s efforts in advancing the health and well-being of women, girls, and young people.

As UNFPA commemorates 50 years of partnership with the Government of India, this event marks a significant moment in their shared mission to ensure the health and well-being of every woman and young person in India as the nation progresses toward the vision of ‘Viksit Bharat’.

Dr Indu Grewal, Additional Commissioner (Family Planning/Pre-Conception and Pre-Natal Diagnostic Techniques/ABP), Dr Pawan Kumar, Additional Commissioner (Maternal Health & Immunization), Dr Zoya Ali Rizvi, Deputy Commissioner (Nutrition & Adolescent Health), delegates from UNFPA and other senior officials from the Ministry were also present at the event.

Also Read:Maternal mortality ratio declines by 8.8 percent, says govt

Powered by WPeMatico

FDA Approves New new treatment option for cutting bleeding in Hemophilia A or B

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are unable to clot properly and may bleed for a longer time than normal after injury or surgery.

The U.S. Food and Drug Administration has approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies).

The FDA  has granted the approval of Hympavzi to Pfizer Inc. Earlier the FDA  had granted Hympavzi Orphan Drug designation for this application.

“Today’s approval of Hympavzi provides patients with hemophilia a new treatment option that is the first of its kind to work by targeting a protein in the blood clotting process,” said Ann Farrell, M.D., Director of the Division of Non-Malignant Hematology in the FDA’s Center for Drug Evaluation and Research. “This new type of treatment underscores the FDA’s commitment to advance the development of innovative, safe and effective therapies.”

Hympavzi is a new type of drug that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated. This is expected to reduce or prevent the frequency of bleeding episodes.

Hympavzi’s approval is based on an open-label, multi-center study in 116 adult and pediatric male patients with either severe hemophilia A or severe hemophilia B, both without inhibitors. For the first six months of this study, patients received treatment with replacement factor either on-demand (33 patients) or prophylactically (83 patients). These patients then received Hympavzi prophylaxis for 12 months. The primary measure of efficacy of Hympavzi was the annualized bleeding rates of treated bleeds. In the patients receiving on-demand factor replacement during the first six months of the study, the estimated annualized bleeding rate was 38 compared to the estimated annualized bleeding rate during treatment with Hympavzi of 3.2, showing that Hympavzi was superior to on-demand factor replacement. In the initial six-month period during which patients received prophylactic factor replacement, the estimated annualized bleeding rate was 7.85 and was 5.08 during the subsequent 12 months on Hympavzi prophylaxis, showing that Hympavzi provided similar bleeding rates.

Hympavzi comes with warnings and precautions about circulating blood clots (thromboembolic events), hypersensitivity and embryofetal toxicity.

The most common side effects of Hympavzi are injection site reactions, headache and itching (pruritis).

Powered by WPeMatico

Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic peripheral neuropathy in India

Mumbai: Alkem Laboratories Ltd. has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc to develop, manufacture and commercialise the drug candidate “SON-080” for the treatment of diabetic peripheral neuropathy in India.

“SON-080” is Sonnet’s proprietary version of “atexakin alfa”. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls.
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.
India is grappling with a substantial burden of diabetes-related complications with diabetic peripheral neuropathy being a major one. Diabetic peripheral neuropathy is notably widespread, affecting up to 62% of people with diabetes mellitus in India. Diabetic peripheral neuropathy primarily affects the hands and lower limbs. It can result in a loss of protective sensation, making individuals more prone to unnoticed injuries, particularly to the feet. Over time, this can lead to the development of serious complications, including amputation.
Dr. Akhilesh Sharma, President and Chief Medical Officer of Alkem said, “We are pleased to partner with Sonnet for this programme. We believe “SON-080” is a unique asset that has demonstrated promising disease modifying potential for diabetic peripheral neuropathy with translational studies showing nerve regeneration.
There is a large prevalence of diabetic peripheral neuropathy in India, which we believe underscores the need for the drug development in this territory and potential value.”
Pankaj Mohan, Founder and Chief Executive Officer of Sonnet, said, “We are excited to partner with Alkem and look forward to advancing “SON-080” into phase 2 clinical development. We believe that Alkem is the ideal partner with significant experience and expertise.”
“SON-080” has undergone many years of development and the previous clinical trials have generated safety data from over 200 patients. “SON-080” has demonstrated compelling preclinical efficacy data in both diabetic peripheral neuropathy and chemotherapy induced neuropathy, including the ability to prevent the development of neuropathy and reverse established neuropathy when assessed by nerve conduction, histological integrity and sensorimotor function measurements.

Powered by WPeMatico

BHMS admissions: KNRUHS invites applications from Management Quota candidates, details

Telangana: Kaloji Narayana Rao University of Health Sciences (KNRUHS) has begun the application process for under Management Quota BHMS course admissions 2024-25.

All the eligible candidates can register for admission into BHMS course in Private Homeopathy colleges affiliated to KNRUHS till 6.00 P.M. on 16-10-2024 through website.

ELIGIBILITY:

i) Candidates from all over the country are eligible for admission into Management Quota seats (Category-B and C) for BHMS Course and as per NCH / KNR University of Health Sciences Regulations.

ii) The candidate should have passed Intermediate (10+2 pattern) or its equivalent examination with Physics, Chemistry, Biology (Botany, Zoology) / Biotechnology and English.

a. OC candidates should obtain not less than 50% marks in science subjects.

b. BC/SC/ST candidates should obtain not less than 40% marks in science subjects.

c. OC PWD candidates should obtain not less than 45% marks in science subjects.

iii) Candidates should have qualified at NEET UG – 2024

iv) The candidates should secure the following cut-off scores in NEET UG-2024.

Category

Qualifying criteria

Cut off score for

eligibility

General category

50th Percentile

162

SC/ST/BC Category

40th Percentile

127

Persons with disability

(OC)

45th Percentile

144

v) Lower percentage / percentile of marks for SC/ST/BC/PWD is only for eligibility purpose and will not be applicable for reservation as there are no reservation quotas for these categories.

vi) Foreign Students / NRI candidates are eligible for admission into AYUSH Courses under Management Quota Category – C Seats.

vii) Candidates who have already applied for Competent Authority Quota have to apply separately if interested for Management Quota admission

viii) Candidates possessing qualification of the University / Board of an institution outside the Telangana State should submit Eligibility / Equivalence certificate from the Board of Intermediate Education of Telangana, to the effect that the qualification possessed is equivalent to Intermediate examination conducted by the Board of Intermediate Education of Telangana at the time of admission into the college.

ix) Candidates possessing qualification of the University / Board of an institution outside INDIA should submit Eligibility / Equivalence certificate issued by Association of Indian Universities, New Delhi and Eligibility / Equivalence certificate issued from the Board of Intermediate Education of Telangana to the effect that the qualification possessed is equivalent to Intermediate examination conducted by the Board of Intermediate Education of Telangana at the time of admission into the college.

AGE: The candidate should have completed 17 years of age as on 31-12-2024. The candidates who do not complete 17 years as on 31-12-2024 is not eligible for admissions.

MERIT LISTS:

The final merit position of the candidates who have applied online in response to the notification issued by KNR University of Health Sciences for Management Quota seats into BHMS course shall be determined by NEET-UG2024 scores and as per their eligibility criteria, applicable regulations, guidelines

The University will release final merit list of eligible candidates for exercising web options after verification of original certificates by the University and officials of concerned departments.

Note: Candidates who have applied online in response to this office notification for determining merit position for Management Quota seats shall upload the original certificates online along with the application. Candidates have to submit one set of print out of application form, original certificates and self attested copies of certificates at allotted college at the time of admission for verification. In case of any discrepancy, allotment of admission is cancelled.

COUNSELING

Provisional final merit list will be displayed on KNRUHS website after scrutiny of original certificates and application. Notification for exercising web options will be issued separately on KNRUHS website only. No individual communications will be sent. Candidates are informed to check the website regularly for notifications.

Allotment of seats: Allotment of seats shall be done through web-counseling by the Committee of Admissions appointed by Competent Authority duly considering the web-options of the candidate by merit.

G. Selected candidates have to join the college within the specified date by submitting all Original Certificates, Bond, and pay the tuition fee as fixed by the Government to complete the process of admission. If the candidate does not report within the specified time and complete the process as described before the admission will be automatically cancelled.

University fee : Candidates have to pay the University fee as detailed below by way of payment gateway and obtain the allotment letter.

Category

BHMS Course

B-Category

15,000=00

C-Category 

Tuition fee: As notified by the Government of Telangana (notified on KNRUHS website).

Note : The candidates selected against Management Quota Category-B & C Seats shall submit the tuition fee notified for Management Quota seat on the day of reporting in the form of Demand Draft in the name of the Principal of the respective college on the day of admission to the college. If the candidate fails to pay the tuition fee within the time of joining, the admission will be cancelled automatically.

On-line Application Form :

i) The On-line Application Form for determining merit position in respective categories for management quota seats using NEET UG – 2024 scores will be available on the website https://tsbhmsmq.tsche.in from 08.00 AM on 09.10.2024 up to 6.00 PM on 16 .10.2024.

ii) The candidate should fill the online application form available in the Website with the data required-for, through internet. The online application form can be filled through any computer with internet connection (home/internet cafe/net center).

The candidate is advised to fill the online application form after going through the Prospectus by keeping all the Certificates ready to enter his/her correct data.

iii) On-line application form without uploading mandatory Certificates, Passport size photo, without signature at declaration area, incomplete applications will be automatically rejected and will not be considered for determining the Merit position in respective categories using NEET– UG – 2024 Rank. Registration and Processing fee is Rs. 4000/- (Bank transaction charges extra).

Procedure of filling online application and Procedure for online payment:

The candidates are advised to take a print out of the Prospectus / Instructions to fill the Application from the website  before proceeding to fill the application form

Read the Notification, Prospectus / Regulations carefully.

Visit website through Internet to fill the application form.

keep the following required documents ready:

a) Latest Passport Size Photo

b) Admit card of NEET UG – 2024

c) Score card of NEET UG – 2024

d) SSC or equivalent examination certificate containing the Date of Birth.

e) Memorandum of marks of qualifying examination i.e., Intermediate or Equivalent examination.

f) Transfer certificate (T.C)

g) Latest Permanent Caste certificate issued by the competent authority of Govt. of Telangana, if applicable. Latest Category certificate in case of BC/SC/ST candidates issued by Competent Authority if applicable ( for NEET Cut-off score under category) .

h) Aadhar Card.

The fee can be paid through Debit card / Credit card or Net Banking.

The fee paid by the applicants is not refundable and not adjusted to a future date under any circumstances.

The candidate should sign at the declaration area in the print out of the online application form.

The candidate should paste a passport size photograph which is similar to that applied for NEET-UG 2024 in the space provided in the print out of online application form and submit at the time of admission.

The University shall conduct verification of uploaded original certificates and notify the merit list on KNRUHS web site.

The candidates shall exercise web-options as per the schedule notified by the University on KNRUHS website.

PROCEDURE FOR SUBMISSION OF ONLINE APPLICATION FORM FOR DETERMINATION OF MERIT POSITION:

Open the website Home page displayed as follows.

There are 4 steps to register for UG admission program i.e

a. Mobile and Email Registration,

b. Candidate Registration (Payment of fee),

c. Updating of data

d. Uploading of Certificates.

2. Monitor Resolution to be set to maximum, Best viewed in 1920 X1080 pixels.

3. Click on the Mobile and Email Registration. The candidate should have a valid /working Mobile and Email Id. OTP will be sent to registered Mobile and Email Id at different stages. The candidate should keep the Mobile and Email Id active till completions of the counselling process. The candidate has to enter OTP’s received to mobile and Email Id for registration and Verification of Mobile and Email Id.

4. After entering the details click on validate button.

5. If all the details entered are correct and verified with OTP’s your system will display a successful message and proceed to registration form

6. Registration Form appears in which Candidate has to give the details. 

7. After entering the details click on validate button it will take you to the Payment Gate way for payment fee.

8. If all the details entered are correct your system will display payment reference number Button to proceed for payment. Depending on your caste category the Registration fee is varied. Once paid you will not get any refund. Hence, you are requested to double check the eligibility conditions mentioned in the Prospectus yourself and pay the fee.

9. Now you will be directed to the Payment Gateway, Click OK

10. Select mode of payment

11. After payment you will receive a Successful Payment message on the screen and you will receive the Registration number to your mobile. Please note down the registration number for further correspondence.

COUNSELLING PROCEDURE FOR ALLOTMENT OF SEATS:

i. The seats as per the notified seat matrix shall be filled through web based counseling by the Committee for Admissions as per merit from the candidates who have qualified in NEET UG – 2024 exam and applied in response to notification by KNR UHS for Management quota seats ( B&C Categories).

ii. University will conduct verification of original certificates and notify the provisional final merit list on the website. University will issue notification for schedule of exercising web options. Candidates are permitted to exercise web options for each phase of counseling. If a candidate does not join after allotment, he/she will not be considered for selection at the subsequent phases of counseling.

iii. Provisional Selection shall be made by the Selection Committee constituted by the University

iv. Candidates shall exercise web-options in order of their priority for Management quota seats in order of MQ1 followed by MQ2 category

v. The selection committee will select the candidates as per the eligibility of the candidate for MQ1 and MQ2 categories and as per the priorities exercised by the candidate. The list of provisionally selected candidates will be displayed and the provisional selection intimations will be issued to the selected candidates.

vi. Candidate after selection has to download the allotment letter, report to the Principal of the allotted college before the last date for joining, pay the fees, submit

original certificates and submit the bond to complete the process of admission.

vii. If a candidate fails to complete the admission procedure after his/her selection, the

allotment stands cancelled automatically. If a candidate does not exercise web options in the first phase, he/she will not be considered for selection at the subsequent phases of counseling.

viii. Candidate after admission in to a college can withdraw from the course, before the last date of free exit for Management Quota, AYUSH admissions to be notified by the University on its website without any penalty.

ix. Vacant seats after first/second round of counseling will be filled up in subsequent phases of counseling by web-options exercised by the candidates during subsequent counseling and allotment list shall be notified on KNRUHS web-site.

x. The Selection Committee shall have power to review the provisional selection in case of any errors, misrepresentation, fraud or glaring injustice.

xi. In all matters relating to selections and admissions, the decision of the selection committee shall be final and binding on the candidates and selections cannot be questioned after admissions are closed.

CLOSURE OF ADMISSIONS:

The admission shall be closed as per NCISM/NCH schedule. Any vacancy after closure of admission or that arises after closure of admission shall not be filled.

Admitted candidates shall follow the regulations issued by Apex bodies i.e., NCH and Ministry of AYUSH from time to time. 

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/20241008062154ug-homeo-mq-prospectus-2024-25-ok-256006.pdf

Powered by WPeMatico

UP Govt Hospitals to get separate medicine counters for journalists soon

Lucknow: Uttar Pradesh Deputy Chief Minister Brajesh Pathak announced on Tuesday the establishment of separate medicine counters for journalists in all state-run government hospitals. 

According to the PTI report, Pathak, who holds the portfolio of the Health Department, issued the order in this regard to the principal secretary, an official statement here said.

Also Read:Maha: 24/7 generic medicine stores to be opened in civic hospitals

Pathak issued the order after a delegation of Uttar Pradesh’s accredited correspondents committee led by its president Hemant Tiwari met him and apprised him that earlier there was an arrangement of separate counters for journalists in government hospitals but it was discontinued.

“Due to long queues in general counters at government hospitals it became difficult to procure medicines from there,” Tiwari said, news agency PTI reported. 

Also Read:Govt to open special medical stores for AYUSH medicines: Shri Prataprao Jadhav

Powered by WPeMatico